<DOC>
	<DOCNO>NCT00006033</DOCNO>
	<brief_summary>RATIONALE : Inserting gene interleukin-2 head neck cancer cell may make body build immune response kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether interleukin-2 gene effective methotrexate advance head neck cancer . PURPOSE : Randomized phase II trial compare effectiveness interleukin-2 gene methotrexate treat patient recurrent refractory stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Interleukin-2 Gene Methotrexate Treating Patients With Recurrent Refractory Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy interleukin-2 gene versus methotrexate patient recurrent refractory squamous cell carcinoma head neck . II . Determine safety tolerability interleukin-2 gene patient . III . Compare quality life patient . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive interleukin-2 gene intratumorally day 1 4 week 1 , weekly 12 week absence disease progression unacceptable toxicity . Arm II : Patients receive methotrexate IV weekly . Treatment continue absence disease progression unacceptable toxicity . Quality life assess begin study week 5 , 13 , 17 25 . Patients follow every 2-3 week 18 week . PROJECTED ACCRUAL : A total 80 patient ( 40 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory stage III IV squamous cell carcinoma head neck Failed first line chemotherapy advance recurrent disease Measurable disease accessible direct injection Tumor must involve major blood vessel obstruct airway PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : No active liver disease Transaminases great 3 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No respiratory disease sufficient enough influence oxygenation arterial blood Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception At least 2 week since prior infection No concurrent infection No active clinically relevant viral illness No clinical condition ( e.g. , effusion ascites ) would preclude methotrexate administration No known hypersensitivity antimetabolite chemotherapeutic agent No rheumatic autoimmune disease No concurrent malignancy require treatment PRIOR CONCURRENT THERAPY : Biologic therapy : No prior antitumor therapy recombinant DNA product include viral base gene therapy bacterial plasmid At least 28 day since prior immunotherapy least 14 day since complete recovery At least 14 day since complete recovery prior antiviral therapy No concurrent hematopoietic growth factor ( filgrastim ( GCSF ) sargramostim ( GMCSF ) ) No concurrent recombinant interleukin2 therapy Prior GCSF GMCSF adjunct therapy allow Chemotherapy : See Disease Characteristics At least 28 day since prior chemotherapy least 14 day since complete recovery No prior methotrexate Endocrine therapy : No concurrent corticosteroid Radiotherapy : At least 28 day since prior radiotherapy least 14 day since complete recovery Surgery : No planned surgical resection Other : At least 14 day since complete recovery prior antibiotic therapy No concurrent high dose nonsteroidal antiinflammatories immunosuppressive drug At least 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>